Appointment and reappointment to the Institute for Research in Immunology and Cancer of the Université de Montréal Board of Directors Français
News provided by
Institut de recherche en immunologie et en cancérologie de l'Université de MontréalAug 07, 2017, 10:00 ET
MONTREAL, Aug. 7, 2017 /CNW Telbec/ - The Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal (UdeM) is pleased to announce that the UdeM Executive Committee has reappointed Mr. Robert Tessier as Chairman of the Board and has appointed Ms. Lucie Rémillard as a Board member.
The IRIC welcomes with great enthusiasm Mr. Tessier's reappointment and looks forward to his three-year mandate. Mr. Tessier is also Chairman of the Board of Directors of the Caisse de dépôt et placement du Québec.
Drawing on 12 years of active involvement with the organization, Mr. Tessier, as Chairman of the Board, will be surrounded by a team of dedicated collaborators sharing a wealth of expertise and various academic, business and philanthropic networks which they may call upon.
The IRIC will now be able to rely on the support of Lucie Rémillard, a corporate director with an extensive knowledge of the philanthropic sector acquired over the years, on the multifaceted work experience of Frédéric Bouchard, Dean of the Faculty of Arts and Sciences (FAS) of the UdeM, as well as the dedication of current Board members: Dr. Marie-Josée Hébert, Vice-Rector of Research, Discovery, Creation and Innovation at the UdeM, Dr. Hélène Boisjoly, Dean of the UdeM's Faculty of Medicine, Jacques Bernier, Managing Partner at Teralys Capital, Marie-Josée Coutu, President of the Marcelle and Jean Coutu Foundation, Jean Royer, Vice-President of Distinction Capital, Michel Bouvier, Chief Executive Officer and Principal Investigator at the IRIC, and Marc Therrien, Scientific Director and Principal Investigator at the IRIC.
"The IRIC is truly fortunate to be able to count on a Board of such high calibre which, through its commitment and dedication to research, continues to support the Institute's objectives and development."
– Michel Bouvier, Chief Executive Officer and Principal Investigator at the IRIC
The IRIC would like to take this opportunity to extend its heartfelt thanks to the Board's outgoing members for their involvement and unwavering support throughout their mandate. Many thanks to Tania Saba, former interim Dean at the UdeM's FAS as well as Tenured professor of the UdeM, to Gérard Boismenu, Vice-Rector of Academic Development and Institutional Transformation of the UdeM, to Johane Boucher-Champagne, former Chair of IRICoR's Board of Directors, and Jacques Parisien, director and advisor for several Canadian companies.
About the Institute for Research in Immunology and Cancer (IRIC)
An ultra-modern research hub and training centre located in the heart of the Université de Montréal, the Institute for Research in Immunology and Cancer (IRIC) was created in 2003 to shed light on the mechanisms of cancer and discover new, more effective therapies to counter this disease. The IRIC operates according to a model that is unique in Canada. Its innovative approach to research has already led to discoveries that will, over the coming years, have a significant impact on the fight against cancer.
For more information: www.iric.ca/en/
SOURCE Institut de recherche en immunologie et en cancérologie de l'Université de Montréal
or interviews: Catherine Cardinal, Chief, Communication and media relations, 514 343-6111, ext. 41299, [email protected]; Cristina Annunzi, Advisor, Communication and media relations, 514 343-7283, [email protected]
Share this article